Two more novel lipid-lowering therapies based on silencing specific genes involved in lipid metabolism have shown promising preliminary results in initial clinical trials. The idea of using small pieces of RNA, known as small interfering RNA (siRNA) specific for a certain gene to switch off the activity of that gene is a new area [...]
Marc Schegerin, chief financial officer of ArQule, discusses ArQule's breakout year including data showing clinical efficacy of ARQ 531 in CLL and the initiation of its MOSAIC trial
In reporting findings from the phase 2b Insulin Liver Effect (ISLE-1) trial, the researchers also found that participants with a high baseline HbA1c assigned to hepatocyte-directed vesicle (HDV) insulin lispro experienced similar HbA1c reductions while using 25% less mealtime insulin with less hypoglycemia. HDV technology is designed to be mixed with any commercially available [...]
After four decades, it’s time to get our summers back. This time of year in New England should mean beach days, ice cream, hikes in the mountains. Instead, for thousands of residents, year in and year out, it means a debilitating bout of Lyme disease, the often-painful tick-borne bacterial illness that arrived with day-glo [...]
If you know that there’s a way to detect cancer early, would you get screened? Many people would say yes, but statistics disagree. About 40 percent of Americans do not get screened for colorectal cancer because they refuse to get or cannot get a colonoscopy. According to the American Cancer Society, 51,000 people in the [...]
BrainsWay’s so-called depression helmet—which focuses powerful electromagnetic waves to stimulate and help rewire neurons firing deep within the brain—picked up its second clearance from the FDA last August, making it the first noninvasive device for obsessive-compulsive disorder.
Scientist Wenning Qin holds up a Petri dish, carefully sloshes around the pink liquid inside, and slides it under a microscope. Some identical tiny slashes come into focus. These cells, she explains, are derived from the ear of a pig. And they may contain the future of animal to human organ transplantation.Click edit button [...]
ProQR Therapeutics, a company focused on treating rare diseases, announced plans to advance its pipeline of RNA medicines to treat inherited retinal diseases to include two fully approved commercial products in Europe and the U.S., three late-stage clinical therapies and seven early-stage therapies by 2023.
The executives at Alkahest have heard plenty of vampire jokes. They are, after all, turning to blood from young donors in search of an elixir for diseases associated with aging. And yes, they’re in Silicon Valley. But this five-year-old biotech company led by Genentech alums is doing serious science.
Abpro is partnering with China-based NJCTTQ to develop new bispecific antibodies using its antibody discovery platform. Under the agreement, Abpro could collect up to $4 billion, which includes $60 million in “near-term R&D funding,” as well as milestone payments and royalties.
United Therapeutics $UTHR is paying an $800 million cash upfront in a big bet to stay among the leaders in pulmonary arterial hypertension, grabbing rights to Arena Pharmaceuticals’ ralinepag in the deal. And the executive crew is willing to add hundreds of millions more in milestones if they can stay on track through to an approval and commercialization. [...]
